MXE was designed in part in an attempt to avoid the urotoxicity associated with ketamine abuse; it was thought the compound’s increased potency and reduced dose would limit the accumulation of urotoxic metabolites in the bladder. Like ketamine, MXE has been found to produce bladder inflammation and fibrosis after high-dose, chronic administration in mice (although the dosages used were quite large). Reports of urotoxicity in humans have yet to appear in the medical literature. MXE is for sale online.